Perspectives
perspectives
June 3rd, 2026
What Pharma Can Learn from Data Science Outside the Industry
perspectives
May 19th, 2026
Turning Real-World Data into Reliable Evidence: The Role of Data Science
perspectives
May 13th, 2026
Beyond Data Cleaning: A Strategic Shift for Clinical Data Management under ICH E6 (R3)
perspectives
May 5th, 2026
A Statistician's Reflection: FDA Guidance on Limiting Crossover in Oncology Studies
perspectives
April 27th, 2026
From Stigma to Signal: The Executive Order, CNPV Vouchers, and What Comes Next for Psychedelics
perspectives
April 20th, 2026
The FDA Drug Shortage List Signals Deeper Concerns for the US Medicine Supply Chain
perspectives
April 15th, 2026
Decision-Making in Early-Phase Oncology Trials: Navigating Uncertainty with Evidence Frameworks
perspectives
April 8th, 2026
Four Pillars of My Success as a Clinical Trial Transparency Specialist
perspectives
March 25th, 2026
REMS and Labeling Are Strategic Design Decisions, Not Late-Stage Add-Ons
perspectives
March 12th, 2026
AI in Pharma: Autopilot Is Not the Same as Removing the Pilot
perspectives
March 3rd, 2026
Modeling and Simulation in Clinical Trials: A Practical Approach to De-Risking Study Design
perspectives
February 25th, 2026
Integrating AI and Automation Into Clinical Trial Operations With Discipline and Transparency